To date, assays of core neuropathology, for example, amyloid‐β (Aβ) and tau protein with positron emission tomography (PET) or in cerebrospinal fluid (CSF), have been validated to have a high accuracy for AD diagnosis in vivo, and have been included in recent criteria for AD research.1, 2. This evidence concerns the gene MAPT and Alzheimer disease.